GlassScriptPhysician profile
Morris L Roebuck
NPI 1356554620
$12,425.75
in general payments reported to CMS, 2019-2025
46 companies · $1,493 in 2025
The $1,493 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $2,107 · 2021: $2,349 · 2022: $1,920 · 2023: $1,466 · 2024: $1,491 · 2025: $1,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,450.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,748.95 | 2019-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $1,268.20 | 2019-2025 | |
| Lilly USA, LLC | $1,244.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,012.92 | 2019-2025 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $908.10 | 2021-2025 | |
| Novo Nordisk INC | $807.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $707.99 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $684.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $620.60 | 2019-2025 | Shingrix, Arexvy, Boostrix |
| E.R. Squibb & Sons, L.L.C. | $390.11 | 2019-2022 | |
| Ucb, INC. | $288.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $287.71 | 2019-2022 | |
| Daiichi Sankyo INC. | $285.52 | 2019-2022 | |
| Janssen Biotech, INC. | $275.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $262.49 | 2019-2023 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $165.09 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.42 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $155.19 | 2019 | |
| Merck Sharp & Dohme LLC | $140.93 | 2020-2025 | Capvaxive, Verquvo, Belsomra |
| Exact Sciences Corporation | $90.32 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $76.88 | 2019-2023 | |
| Celgene Corporation | $75.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $69.78 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $60.76 | 2023-2025 | Gvoke Hypopen |
| Radius Health, INC. | $59.76 | 2019-2022 | |
| Allergan, INC. | $58.34 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $54.01 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.70 | 2022 | |
| Amarin Pharma, INC. | $34.21 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $32.77 | 2023 | Gemtesa |
| Endogastric Solutions, INC | $30.01 | 2024 | Esophyx |
| Vifor Pharma, INC. | $28.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.88 | 2022-2025 | Zoryve |
| Tersera Therapeutics LLC | $26.44 | 2022 | |
| Beta Bionics, INC. | $23.52 | 2024 | Ilet Bionic Pancreas |
| Soleno Therapeutics, INC. | $22.74 | 2025 | Vykat Xr |
| Boston Scientific Corporation | $22.46 | 2023 | Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $22.03 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.48 | 2025 | Xhance, Nuzyra |
| Horizon Therapeutics Plc | $20.58 | 2023 | Krystexxa |
| Corcept Therapeutics | $19.07 | 2023 | Korlym |
| Abbott Laboratories | $18.18 | 2024 | Freestyle Libre |
| Sanofi Pasteur INC. | $17.62 | 2023 | |
| Pulmonx Corporation | $16.26 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Esperion Therapeutics, INC. | $16.20 | 2025 | Nexletol |
| Lundbeck LLC | $15.39 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Roebuck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.